Health
Melatonin could act as barrier against SARS-CoV-2 infection – Drug Target Review
Researchers have suggested using melatonin in a nasal spray to create a protective barrier against SARS-CoV-2 in pre-symptomatic patients.
Posted: 28 January 2021 | Victoria Rees (Drug Target Review) | No comments yet
Researchers have suggested using melatonin in a nasal spray to create a protective barrier against SARS-CoV-2 in pre-symptomatic patients.
According to a new study, melatonin synthesised in the lungs could act as a barrier against SARS-CoV-2, preventing expression of genes that encode proteins in cells such as resident macrophages in the nose and pulmonary alveoli and epithelial cells lining the alveoli, all of which…
-
Noosa News24 hours agoChild sex offenders to be known in Queensland public registry
-
General24 hours agoThousands flood cities demanding action on Palestine
-
General23 hours agoNRLW Sunday: Brisbane Broncos hammer Newcastle Knights, Cronulla Sharks move to third on ladder
-
General14 hours agoFirst home buyers score early access to deposit scheme